Distinct Parameters in the EEG of the PLP α-SYN Mouse Model for Multiple System Atrophy Reinforce Face Validity

Lorenz Härtner1, Tobias W M Keil1, Matthias Kreuzer2

  • 1Department of Pharmacology and Toxicology, Institute for Pharmacy, Leopold-Franzens University of Innsbruck Innsbruck, Austria.

Insights

This study investigates sleep disturbances in the PLP α-SYN mouse model of Multiple System Atrophy (MSA). Findings reveal age-dependent EEG spectral shifts and REM sleep muscle activity, supporting the model

Area of Science:

  • Neuroscience
  • Sleep Medicine
  • Animal Models

Background:

  • Multiple system atrophy (MSA) is a neurodegenerative disorder with parkinsonian and cerebellar symptoms.
  • Sleep disturbances are a significant feature of MSA, impacting patient quality of life.
  • The PLP α-SYN mouse model is crucial for MSA research, but its sleep characteristics remain unstudied.

Purpose of the Study:

  • To investigate sleep disturbances in the PLP α-SYN mouse model of MSA.
  • To assess the face validity of the PLP α-SYN model for studying MSA-related sleep issues.
  • To identify potential biomarkers for future therapeutic development in MSA.

Main Methods:

  • Electroencephalography (EEG) to analyze brain activity during sleep.
  • Electromyography (EMG) to characterize muscle activity during REM sleep.
  • Age-dependent analysis of EEG and EMG data in the PLP α-SYN model.

Main Results:

  • Identified spectral shifts in EEG, mirroring findings in human MSA patients.
  • Characterized muscle activity during REM sleep, relevant to REM sleep behavioral disorder.
  • Demonstrated age-dependent changes in both spectral shifts and REM sleep muscle activity.

Conclusions:

  • The PLP α-SYN mouse model exhibits age-dependent sleep disturbances, supporting its face validity for MSA research.
  • The identified EEG and muscle activity patterns serve as potential biomarkers for evaluating therapeutic interventions.
  • Further studies are recommended to evaluate the predictive validity of this model for MSA treatments.